Virtual Medication-Assisted Treatment Waiver Training

Actions and Detail Panel

Sales Ended

Event Information

Share this event

Date and Time



Online Event

Event description
Graduate Medical Education on Treatment of Opioid Use Disorder

About this Event

Distinguished Speakers

Jason Beaman, D.O., M.S., M.P.H., FAPA

Chair, Department of Psychiatry and Behavioral Sciences

Assistant Clinical Professor

OSU Center for Health Sciences

Half & Half Training Model:

Trainees attend this 4 hour live training taught by clinical expert, Dr. Jason Beaman. Once completed, participants will receive the second half of the course – a 4 hour online self-study portion. At the end of the course, participants are required to pass an exam with a 75% or higher before applying for their waiver.


  • As a requirement of PCSS-U and to validate your attendance, your video will be required to be on for the duration of the training. Please have your audio muted.
  • In addition, a polling question will be asked each hour to validate attendance
  • Please note: Our instructors will be available throughout the training to answer questions. Additionally, instructors will be available for follow up questions for a week after the training, should additional questions come up. Your inquiries will be addressed within a week

Medication- Assisted Treatment Training:

“OSU Medicine is committed to expanding access to treatment for Oklahomans who suffer from opioid use disorders through physician training. As a land-grant university, we are here to serve our fellow Oklahomans in their time of need.” – Dr. Kayse Shrum, President, OSU Center for Health Sciences.

The purpose of this is to better prepare physicians and medical students to identify individuals with opioid use disorders and to engage those patients in medication-assisted treatment for their opioid use disorder.

  • Screen and identify patients with OUD and define evidence-based treatments.
  • Discuss the pharmacology of opioids as it relates to treatment of opioid use disorder (OUD) patients.
  • Describe the fundamentals of office-based opioid treatment including the treatment of the co-morbid patient.
  • Explain the process of buprenorphine induction as well as stabilization and maintenance.
  • Discuss all FDA approved antagonist and agonist medications to treat OUD.
  • Discuss basic office protocols including medical record documentation and confidentially.
  • Utilize evidence-based resources to ensure providers have the confidence to prescribe buprenorphine for patients with OUD.
  • Recognize the importance of obtaining a waiver to begin treating patients with OUD.


The OSU-COM Continuing Medical Education office designates this program for a maximum of 4 AOA Category 1-A credits and will report CME and specialty credits commensurate with the extent of the physician's participation in this activity.

Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

The American Academy of Addiction Psychiatry is approved by the Drug Abuse Treatment Act of 2000 (DATA) to provide the required eight-hour training that qualifies physicians for the waiver to prescribe Buprenorphine for treating opioid use disorders. AAAP is the Data Sponsor for this event.

		Virtual Medication-Assisted Treatment Waiver Training image

		Virtual Medication-Assisted Treatment Waiver Training image

Date and Time


Online Event

Save This Event

Event Saved